AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
Arrow is the marketing partner in US
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
Medanta expanded its bed capacity by 20% during the year
The facility combines advanced diagnostics, bone marrow transplant evaluation, prenatal awareness, and multidisciplinary support services
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
